Tejal Somvanshi
If your weight or blood sugar has stalled on the highest approved dose of Ozempic, you may wonder whether something stronger exists. Eli Lilly says a new head-to-head trial suggests its experimental drug, retatrutide, does better on weight and on blood sugar. Retatrutide is not yet approved, so it is not available at pharmacies.
The Eli Lilly retatrutide vs Ozempic trial compared its drug with semaglutide 2 mg, the highest US-approved Ozempic dose for type 2 diabetes. Lilly released the results on October 28, 2026. The randomized, open-label trial enrolled 1,298 adults with type 2 diabetes. In the trial, retatrutide at 9 mg and 12 mg cut body weight by 19.5% and 20.9% over 80 weeks. Ozempic 2 mg cut it by 9.4%. Both retatrutide doses also lowered HbA1c, the blood sugar test that reflects average glucose over about three months, by 2.2 percentage points. Ozempic 2 mg lowered it by 1.8 percentage points. Only the 12 mg dose's advantage on HbA1c is statistically controlled for multiple comparisons. Stopping treatment because of side effects was more common on retatrutide: 4.8% on the 9 mg dose and 7.9% on the 12 mg dose, against 2.7% on semaglutide. Lilly describes retatrutide as a triple agonist. It targets three hormone receptors: GLP-1, GIP and glucagon. Ozempic targets only GLP-1.
If you take the 2 mg dose of Ozempic, this trial does not change your prescription today. Retatrutide is investigational and has not been approved by the FDA, so it cannot be filled at a US pharmacy. Ask your doctor about approved options you can use now, such as Zepbound, which targets two hormone receptors. Do not stop or change your medicine based on this report alone.
How the Triple-Hormone Mechanism Works
Ozempic works through one hormone signal. Its active ingredient, semaglutide, copies GLP-1. That hormone slows stomach emptying and tells the brain you are full. Retatrutide adds two more targets. GIP is a hormone that helps control insulin release. Glucagon usually raises blood sugar when levels fall, so its role in weight loss is less well understood. Think of Ozempic as one dial on a control panel and retatrutide as three dials turned at once. Researchers will want to know how much each signal contributes. The full data have not been presented yet. For background on how Ozempic compares with Zepbound, see our earlier coverage.
The comparison dose matters. Ozempic 2 mg is a diabetes dose, and the trial compared retatrutide with it, not with the higher doses sold for weight loss. That makes a doubling of weight loss in a diabetes group a bigger clinical point than the headline suggests. This is our reading of the trial design, not a conclusion Lilly stated.
Can you get retatrutide prescribed in the US right now?
No. Retatrutide has not been approved by the FDA, so US pharmacies cannot fill it. Retatrutide is investigational and not FDA-approved for routine clinical use. Online sellers that offer "compounded retatrutide" are not offering an approved medicine.
Lilly's trial results put retatrutide ahead of Ozempic 2 mg on weight and blood sugar in this study. The next steps are a full data presentation at a medical meeting and an FDA review. Lilly has not announced a US approval date or price. Check back for updates.
Related Karmactive coverage: this report and this earlier coverage. The relevant primary update is available from the official source.
